 |
|
|
| |
Dolutegravir (DTG) Use During Pregnancy and Birth Outcomes: Data from the Antiretroviral Pregnancy Registry (APR)
|
| |
| |
EACS 2019 Nov 6-9 Basel
Reported by Jules Levin
Vani Vannappagari1,2, Jessica D. Albano3, Leigh Ragone1, Taylor Cook3, Angela E. Scheuerle4, William R. Short5, Claire Thorne6, Karen Beckerman7, Hugh Tilson2, Nahida Chakhtoura8, D. Heather Watts9, Lynne Mofenson10
1ViiV Healthcare, Research Triangle Park, NC, USA; 2Gillings School of Global Public Health, University of North Carolina-Chapel Hill, NC, USA; 3Syneos Health, Wilmington, NC, USA; 4University of Texas Southwestern Medical Center, Dallas, TX, USA; 5The Perelman School of Medicine, University of Pennsylvania, Philadelphia PA, USA; 6University College London Great Ormond Street Institute of Child Health, London, UK ; 7Carl Icahn School of Medicine at Mt Sinai, BronxCare Health System, Bronx, NY, USA; 8Eunice Kennedy Shriver NICHD, National Institutes of Health, Bethesda MD, USA; 9Office of the Global AIDS Coordinator and Health Diplomacy, Washington DC, USA; 10Elizabeth Glaser Pediatric AIDS Foundation, Silver Spring MD, USA
|
| |
|
|
|
|
|
